Clinical Trial Update: Amikacin Penetration Into the Cerebrospinal Fluid [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluated amikacin penetration into the cerebrospinal fluid in bacterial meningitis. The study has been withdrawn from the registry.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Meningitis
• Post-traumatic Meningitis

Drugs mentioned

• Amikacin (amikacin)

Snippet

Sponsor: Rambam Health Care Campus | Conditions: Gram Negative Meningitis, Post Traumatic Bacterial Meningitis | Phase 4 | Status: WITHDRAWN